Gilead Sciences (GILD)
(Delayed Data from NSDQ)
$73.78 USD
-0.56 (-0.75%)
Updated Aug 16, 2024 04:00 PM ET
After-Market: $73.77 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$73.78 USD
-0.56 (-0.75%)
Updated Aug 16, 2024 04:00 PM ET
After-Market: $73.77 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth B Momentum A VGM
Zacks News
5 Stocks in the Spotlight on Trump's Coronavirus Vaccine Optimism
by Ritujay Ghosh
Millions are pinning their hopes on a handful of drugmakers, which are into the final phases of their vaccine trial.
The Zacks Analyst Blog Highlights: Google, NVIDIA, Costco, Gilead Sciences and Morgan Stanley
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Google, NVIDIA, Costco, Gilead Sciences and Morgan Stanley
Top Research Reports for Alphabet, NVIDIA & Costco
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Alphabet (GOOGL), NVIDIA (NVDA) and Costco Wholesale (COST).
Ligand (LGND) Beats on Q2 Earnings & Sales, Raises View
by Zacks Equity Research
Ligand (LGND) reports better-than-expected second-quarter 2020 earnings and revenues. Stock up.
Pharma Stocks in Focus on Late-Stage Coronavirus Vaccine Trials
by Ritujay Ghosh
Hopes of a vaccine have once again started rising with a number of companies now entering the final phase of their trials.
Gilead (GILD) Misses on Q2 Earnings & Sales, Ups '20 Guidance
by Zacks Equity Research
Gilead (GILD) reports weaker-than-expected results for the second quarter but ups annual guidance.
Gilead Sciences (GILD) Misses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Gilead (GILD) delivered earnings and revenue surprises of -23.97% and -1.91%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Mylan (MYL) to Report Q2 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
Investors will look forward to regular top and bottom-line numbers and updates on the merger with Upjohn, when Mylan (MYL) reports Q2 results.
Lilly (LLY) Q2 Earnings Top Estimates, Sales Lag, Stock Down
by Zacks Equity Research
Eli Lilly (LLY) reports mixed Q2 results. Total revenues in the quarter hurt by the coronavirus pandemic
Biotech Stock Roundup: Amgen Reports Q2, GILD's CAR T Therapy Gets Approval & More
by Zacks Equity Research
The biotech sector remains in focus with earnings, regulatory and other pipeline updates.
Big Drug Stock Q2 Earnings on Jul 30: LLY, GILD, VRTX & More
by Kinjel Shah
Let us take a look at five big drug/biotech companies, GILD, LLY, VRTX, ALXN, and AZN, gearing up for their earnings release.
Coronavirus Vaccine Development Puts These Stocks in Focus
by Ritujay Ghosh
Moderna and Pfizer launches two 30,000-subject trials of COVID-19 vaccines that could clear the way for regulatory approval and widespread use by the end of this year.
What Lies Ahead for Healthcare ETFs in Q2 Earnings?
by Sweta Killa
The healthcare sector is expected to witness substantial earnings decline of 6.9% in the second quarter, representing the second strongest sector this earnings season.
How Hard Will Coronavirus Hit Lilly's (LLY) Q2 Earnings?
by Zacks Equity Research
Investor focus is likely to be on the extent of the impact of the coronavirus outbreak on Lilly's (LLY) performance when it reports second-quarter earnings.
Markets Remain Calm But More Data and Earnings are Coming
by David Borun
Equities trend sideways as we wait for Congress and 30% of the S&P is set to report results.
Will Coronavirus Woes Impact Gilead's (GILD) Q2 Earnings?
by Zacks Equity Research
Investors will focus on the HIV franchise's performance and the uptake of Yescarta along with updates on experimental coronavirus treatment, when Gilead (GILD) reports second-quarter 2020 results.
Biotech Stock Roundup: BIIB Reports Q2, GILD Acquires Stake in Private Company & More
by Zacks Equity Research
The biotech sector remains in focus with earnings, regulatory and other pipeline updates.
Earnings Preview: Gilead Sciences (GILD) Q2 Earnings Expected to Decline
by Zacks Equity Research
Gilead (GILD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Roche's (RHHBY) 1H20 Sales Hit by the Coronavirus Pandemic
by Zacks Equity Research
Roche's (RHHBY) performance in first-half 2020 was unimpressive as it bears the brunt of the COVID-19 outbreak.
Gilead (GILD) to Buy 49.9% Stake in Private Cancer Drugmaker
by Zacks Equity Research
Gilead (GILD) will acquire a 49.9% stake in Tizona Therapeutics, Inc., a privately-held cancer drugmaker, for $300 million.
Gilead Sciences (GILD) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed the most recent trading day at $78.08, moving +0.74% from the previous trading session.
Bristol-Myers' (BMY) CAR T Cell Therapy Gets EMA Validation
by Zacks Equity Research
Bristol-Myers' (BMY) MAA for its experimental candidate, liso-cel, gets validated by EMA.
Biotech Stock Roundup: GILD, MRNA Give Coronavirus Treatment Updates & More
by Zacks Equity Research
The biotech sector remains in focus with updates on coronavirus treatments and other pipeline updates.
Ceylad Gets FDA Nod to Begin Phase I Study on CAR T Candidate
by Zacks Equity Research
Celyad (CYAD) gets the FDA's permission to begin a phase I study on its lead CAR T candidate, CYAD-211, for the treatment of relapsed/refractory multiple myeloma.
Equillium Gains From Positive Results on Coronavirus Drug
by Zacks Equity Research
Equillium (EQ) soars on positive results on pipeline candidate, itolizumab, for COVID-19.